MedTrace Logo

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

NCT03115827 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-01-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out whether droxidopa, a medication that increases norepinephrine levels, may be effective in improving some aspects of cognition and movement in Parkinson's disease (PD).

Conditions

  • Parkinson Disease

Interventions

DRUG

Droxidopa

Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day

DRUG

Carbidopa

Carbidopa 200mg twice a day

Sponsors & Collaborators

Principal Investigators

  • Katherine McDonell, MD · Vanderbilt Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-18
Primary Completion
2018-12-21
Completion
2018-12-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03115827 on ClinicalTrials.gov